blur line execut pipelin
valu eye glaucoma initi neutral
develop larg grow implant micro-invas
glaucoma surgeri mig devic market treatment multipl stage
glaucoma reimburs clinic outcom procedur simplic
aid adopt ophthalmologist two commerci
avail product istent istent inject layer cataract
competit increas stay step ahead product
pipelin address full continuum glaucoma survey
work kol call note physician see product part
multi-mod treatment strategi panacea growth
expect in-lin current street estim necessarili
much share price today lie pipelin
think istent sa could see strong uptak think less applic
across glaucoma spectrum assum idos limit valu
see beyond current share price today initi neutral
robust pipelin multipl catalyst address full diseas
continuum pipelin numer forthcom product
includ istent infinit istent sa istent supra idos
litani mileston morph
combin pharma-devic compani may culmin idos
offer access ocular diseas beyond glaucoma
survey kol call provid mix view current
futur product high level physician note idos may less
applic certain glaucoma class other current product
usag expect grow line street estim /-
percent year necessarili istent sa
good uptak physician larg shrug hypothet
reimburs chang hamper usag
cypass remov market continu benefit
impress busi model today sale forc abl
gross margin offer sizabl leverag scale
valuat rate neutral risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
develop larg grow implant micro-invas
glaucoma surgeri mig devic market treatment multipl stage
glaucoma reimburs clinic outcom procedur simplic
help improv adopt amongst ophthalmologist two
commerci avail product istent istent inject layer
cataract procedur signific grow diseas burden
glaucoma combin product eas use expect continu
uptak combin cataract procedur addit busi
model impress gross margin among best smid-cap
med-tech sale rep abl drive high product surgeon
commit famili product
competit increas stay step ahead product
pipelin address full continuum glaucoma survey
work kol call note physician see product part
multi-mod treatment strategi panacea growth expect
in-lin current street estim necessarili much
share price today lie pipelin look futur
product believ istent sa present novel stand-alon without need
cataract procedur option treatment mild moder
glaucoma patient market opportun stand-alon treatment
option signific like driver growth
futur physician survey familiar stand-alon treatment
use numer product today believ come
area drive meaning uptak easy-to-us inject sa
signific product pipelin idos forthcom
combin drug-devic guid applic pharmaceut product
layer differ molecul direct applic eye first
applic travoprost prostaglandin analog elut
specifi rate period time note idos travoprost expect
base discount sale model believ idos repres
per share valu today discount sale model assum broad
applic across form glaucoma ocular hypertens
repeat usag annual said note survey work
physician show less interest use devic first line
treatment indic product applic limit
scope glaucoma stage initi assum like put ceil
idos valu project discount sale analysi combin
potenti forthcom product exist busi
today see fairli valu current level would choos
step opportunist level
view becom construct think upon
commerci idos conduct signific clinic educ
help physician becom comfort product within
period time believ view around devic may chang
seen broadli applic stage glaucoma success
chang clinic accept around use
product treatment glaucoma think adopt could
signific assum today lead stronger sale faster growth
multipl wildcard also iron around idos
pharmacoeconom product payer coverag
reimburs level may impact usag adopt physician
gain clariti around topic believ view could chang
becom construct
signific grow diseas burden glaucoma
glaucoma lead caus irrevers visual impair blind
world-wide primari open angl glaucoma poag account
glaucoma case predict increas steadili case
world-wide due global popul demograph age kapetanaki et
al british journal ophthalmolog studi estim global
incid poag case high ww quigley et al british journal
ophthalmolog expect increas case
broad estim suggest global popul year age
current form glaucoma mani undiagnos
glaucoma earli impact asymptomat studi rang
patient undiagnos way look global incid
diseas signific burden show us-bas forecast
diseas race age group suggest signific
increas diseas
figur us glaucoma project race age group
identifi way treat glaucoma reduc intra-ocular pressur
eye mitig progress ocular nerv damag convent
treatment option glaucoma involv use multipl type
prescript eye drop oral medic rest patient life
complex case undergo surgeri statist patient adher
side effect suggest opportun improv newli
prescrib patient dont refil prescript
prescrib patient take med year
grow age world-wide popul econom
consequ glaucoma signific weve yet see studi
categor world-wide econom burden estim us burden
suggest least direct cost increas direct
ophthalmolog relat cost sever increas seen varma et al
studi earli identif treatment patient glaucoma
well ocular hypertens may help reduc econom
qualiti life impact diseas caus
figur increas financi burden glaucoma diseas sever
varma et al american journal ophthalmolog
given incid diseas glaucoma present signific
grow market opportun
pharmaceut perspect global glaucoma market estim
grow compound-annual-growth-rate rise
look sole us franc germani itali spain uk
japan technolog target
pharmaceut surgic opportun combination-bas
blend histor population-bas survey cataract
surgeri data glaucoma prescript data medic claim estim
total poag preval patient us anoth
ocular hypertens precursor mild glaucoma base bilater
incid rate would equat eye treatabl
us alon intern estim limit believ
opportun intern significantli larger vision care mani
countri limit
current within us abl penetr
eye istent istent inject label use
combin cataract procedur upon commerci introduct
futur product istent infinit idos istent sa glauko opportun
expand significantli penetr full eye glaucoma
us
figur us clinic opportun estim eye diseas stage
figur expand us market opportun product
base estim combin market data averag
sale price mig devic estim market opportun current
approv product grow time market opportun
assum increas incid glaucoma gener popul
increas number cataract procedur us modest price eros
mig devic time competit enter market
figur estim us market opportun mig product combin cataract procedur
btig american ophthalm associ ophthalmolog time
us glaucoma market popul primari open angl glaucoma market primari open angl glaucoma cataract surgeri growth cataract procedur potenti mig devic address market opportun combin cataract mig market
market opportun increas significantli introduct
product stand-alone poag requir use combin
cataract procedur may cannib exist
market opportun estim market opportun stand-
alon procedur significantli larger due higher
number patient may address market opportun
estim assum increas incid oag patient time
littl price eros mig devic valu proposit
higher stand-alon procedur estim number diagnos
treatabl eye estim
figur estim us market opportun stand-alon phakic/pseudophak eye
lastli believ introduct idos may expand market
opportun even address glaucom eye includ
ocular hypertens precursor glaucoma addit idos may
like recur treatment option patient time creat
increas patient popul could come back treatment repeatedli
note opportun estim idos inclus
market opportun previous describ patient whether
phakic/pseudophak combin cataract would includ
calcul note one limit analysi believ
difficult handicap proport patient may use mig devic
istent istent inject combin idos would provid
addit market opportun combin therapi grow
popul phakic/pseudophak total oag oag popul phakic/pseuophak eye total dx treat mig devic address market opportun stand-alon mig market
figur estim us market us opportun idos stent
full pipelin across glaucoma diseas continuum
competit grow within mig market form mig
implant devic drug-elut product offer numer
product address progress larger market opportun
nich area supra forthcom product build effici
design origin istent introduct product
istent supra istent infinit idos capabl treat
entir continuum glaucoma diseas product provid
physician new option treatment glaucoma given glauko
exist sale presenc comprehens ophthalmologist segment
believ may less costli make increment sale newer product
exist custom base benefit improv patient
outcom increment asp dollar less time market penetr
lay product pipelin stand today
product address across glaucoma continuum
us popul total us popul year glaucoma market popul primari open angl glaucoma market primari open angl glaucoma poag ocular hypertens market popul oh total total total dx treat potenti idos per md visit per opportun stent market
figur applic respect product
discount sale cash flow analysi suggest idos
add valu share
idos travoprost expect come market late earli
evolv medic technolog compani drug/devic
combin manufactur offer topic therapi direct
anterior chamber eye due elut rate idos run
pharmaceut fill one-year period patient like need
stent replac annual basi may sound inconveni
surfac compar daili routin eye drop oral
medic combin non-compli rate believ
patient may choos idos recur natur busi creat
cascad patient could build time believ gate
factor idos earli may physician accept product
reimburs payer price physician view idos may
front-lin treatment believ work dilig improv
perceiv pharmacoeconom valu idos physician payer
like take time limit earli adopt today base
penetr assumpt idos market model investor valu idos
sale growth discount sale valuat suggest valu per
share base futur revenu assumpt share idos
come market discount rate
figur discount cash flow discount sale valuat idos
idos initi market use travoprost treatment
glaucoma believ exist travoprost market share prescript
eye drop market first segment idos compet accord
iqvia data prostaglandin analog repres drop market
bottl travoprost repres bottl
divid monthli basi yield patient prescrib base
travoprost fulli met idos would repres initi commerci
opportun idos significantli lower market
opportun model devic abl demonstr efficaci
elimin non-compli believ could increas market penetr
beyond exist travoprost drop share grow even
outfit differ iop reduc formul
penetr patient eye patient eye patient eye per idos y/i comp
think istent sa could garner strong uptak
hit market
istent sa expect survey work suggest
physician alreadi use istent product off-label treat stand-alon
glaucoma product devic approxim
respond note use mig devic conjunct cataract
believ encourag sign istent sa given larg proport
patient would qualifi stand-alon treatment physician alreadi
will prepar uptak devic upon approv
estim total address market captiv custom base expect
hit ground run stand-alon market opportun
option area ophthalm treatment
present form idos focus treatment glaucoma
use travoprost consid physic characterist
abil carri molecul direct anterior posterior insert
open varieti treatment option ocular
diseas believ keep plan addit molecul
idos close vest competit reason note treatment
larg ocular condit cytomegaloviru retin macular
degener posterior uveiti could area futur idos
opportun captiv custom base mani physician treat
condit beyond glaucoma idos import tool
expand beyond glaucoma market
gross margin best smid-cap med-tech
enjoy gross margin expect limit
upsid current gross margin level futur year strong gross
margin current enjoy allow compani gener posit
cash flow oper compar high growth medic
technolog compani note gross margin best
compar group yet valuat ev/gross profit multipl
compani buy pt analyst
lavin neutral analyst lavin neutral
analyst lavin compar compani note
posit net margin still neg net
margin believ reach scale begin reflect posit net
incom similar valuat premium could place share
addit believ gross margin highli defens
competit enter mig market price flexibl first
gener istent offer value-ori product compet price
retain higher margin newer gener product
favor facil fee reimburs regardless site
seen improv facil fee use mig
combin cataract surgeri help foster adopt
specif medicar increas rate reimburs ambulatori
surgeri center incentiv usag signific amount
final medicar fee schedul publish earli januari nation
averag medicar payment asc increas
import rememb surgeon implant istent
conjunct cataract surgeri asc reimburs
codein cataract code net
basi asc receiv averag reimburs approxim
combo cataract istent procedur higher
sinc time reimburs rate set held steadi
actual increas modestli support adopt believ base
in-depth analysi reimburs see page combin procedur
rate hospit outpati rate stand
even higher rate hospit set often
effici physician practic also may partial
own said physician regardless site care believ
reimburs rate favor drive adopt leav
facil suffici margin procedur
note reimburs analysi also highlight medicar
administr contractor rate geographi across us
reimburs rate physician mig procedur code
wide variat amongst variou around
payment mig procedur rang physician
cover procedur
neg risk
survey work kol call suggest mix view
conduct survey comprehens ophthalmologist kol call
understand dynam within minim invas glaucoma surgeri mig
devic market survey conduct two-week period late
februari screen comprehens ophthalmologist
multipl year experi perform meaning number cataract
procedur month refer treatment glaucoma
anoth physician number year practic respond group
rang year year mean number year practic
median number year practic number cataract
procedur perform per month rang mean number
median number broad take-away list
comprehens discuss survey pleas click
neg current product usag expect increasebut upsid like
cap line street expect ask increas
istent/ist inject usag conjunct cataract surgeri survey
respond anticip increas amount line street
revenu growth estim penetr approach glauko
assum cataract/glaucoma comorbid limit upsid view
neg physician see idos applic specif glaucoma
popul necessarili popul previous assum
survey work indic physician show less interest use
guid applic pharmaceut devic first line treatment
indic product applic limit scope
glaucoma segment initi assum
posit think istent sa could see broad uptak upon approv
bullish develop come survey work
willing among doc util mig devic treatment glaucoma
outsid cataract surgeri doc alreadi use istent off-label
stand-alone treatment abl expand label gain
reimburs approv includ stand-alone procedur feel
readi popul doctor quickli ramp procedur
posit doc shrug reimburs chang ask
impact reimburs chang expect usag istent
doc view non-factor contrast previou usag
behavior impact reimburs cut medicar
administr contractor indic us like settl term
futur impact reimburs chang
posit cypass remov tailwind istent survey respons
posit shift share away recal cypass
istent sever quarter go fulli lap benefit recal
see tailwind istent sale
lastli note kol call mix well conduct
numer kol call physician avid mig user clinic
trial found respons line survey result notabl
receiv mix feedback istent inject physician spoke
note difficultli place smaller stent within trabecular meshwork
compar previou gener istent like haptic feedback
previou gener product separ physician note
smaller lumen size inject stent led slower aqueou outflow
stent place near outflow pathway trabecular meshwork
aqueou humor outflow impact sampl size regard
feedback pure one physician feedback believ
physician could similar concern issu may larg
mitig addit clinic educ
increas competit public privat
micro-invas glaucoma surgeri mig opportun larg
attract interest multipl compani medic devic side
alcon allergan rate competit suprachordi stent
although alcon remov marketplac due safeti
concern ivanti privat held medic devic compani hydru
stent commerci avail istar medic europ among hand
earli stage glaucoma treatment compani undergo clinic research
studi bring new product market competit section page
pharmaceut perspect compani aeri
rate allergan
rate new pharmaceut formul treatment
wherebi stent either synthet biolog drug compon
elut molecul specif anatomi eye
penetr still less mig market entranc
new competitor could impact abil grow seen result
alcon cypass market offer physician trial
purpos physician util free product impact quarterli
result enter see limit competit risk alcon
market other come marketplac quarterli result
could impact
immedi competit mig space like come
ivanti compani market hydru microst devic
approv use mild moder primari open-angl glaucoma data
present compani compar trial compar hydru two
istent demonstr hydru abl significantli reduc
amount medic use efficaci lower iop compar
two istent month hydru patient istent
patient met studi success level defin reduct
iop reduct one glaucoma medic mean
medic reduct month hydru group
istent group note investor look horizon
trial compar trial understand hydru outcom profil
physician reimburs chang medicar administr
contractor could impact util share
given istent local coverag determin rather nation coverag
determin physician reimburs combo cataract
procedur believ higher likelihood chang
procedur reimburs would procedur rate set
medicar nation level fact instanc
certain modifi payment rate caus investor
concern util would dip due rate chang specif
april noridian propos cut physician payment rate
physician offic procedur share fell
news share ultim recov volatil around
reimburs chang risk neg impact util
devic certain geographi
cannib new product slow top-lin
launch compani second product istent inject follow
initi sale strategi focus convert exist istent user inject
platform strategi led disrupt growth sale forc
focu shift expand surgeon base convert exist surgeon
inject product also destock legaci istent inject
ramp management state like continu
continu shift physician istent inject suffici bolu
physician convert focu sale forc shift back new
given full pipelin new product potenti similar
futur disrupt could occur similarli istent convert istent
inject wrinkl new competit mig space way
potenti compani could face difficult road new
surgeon convers multipl mig player market
istent supra ad risk safeti
one pivot point proposit clinician safeti
profil istent famili devic given clinic data come
around suprachoroid devic endotheli cell loss base safeti
describ depth believ introduc potenti
higher risk product least play alcon cypass
could compromis imag broader compani among
ophthalmologist wake cypass recal notabl
concern fallout broader mig space
feel ophthalmologist discern mig deliveri method istent
trabecular bypass stent cypass suprachoroid stent
wonder last higher risk profil develop around istent
supra find especi relev given view product
oper nich market
price eros product increas
enjoy minim competit implant mig space
move forward trabecular bypass competit come
though clinic data yet fulli releas clinic approv
time devic potenti enter space feel
grow risk declin differenti price eros result given
signific first mover advantag space feel could
risk competitor undercut price tri gain share
consider investor enter new market multipl
treatment option glaucoma patient outsid mig devic much
product develop date glaucoma focus first line
therapi drop last resort trabeculectomi treatment
expand broader rang glaucoma indic compani
need worri price competit mig devic
also pharmaceut laser surgeri tradit surgeri
end believ need justifi econom valu product
incumb
idos adopt guarante
feel strong option treatment oht mild
glaucoma idos treatment offer strong clinic profil
efficaci safeti rival topic drop elimin burden daili
administr risk non-compli said feel devic
sever hurdl clear becom frequent first line treatment first
reluct ophthalmologist prescrib invas procedur
regardless minim invas idos still inher
invas drop initi treatment option larg reason
drop standard first line treatment one factor aid
growth slt first line procedur feel idos unabl
demonstr clinic superior topic prostaglandin struggl
know price idos payer will
pay believ product like price premium altern
pharmaceut option result idos need overcom patient
perceiv valu rel eye drop histor prostaglandin brand
version significantli expens gener market
today believ may play role patient non-compli
push patient altern treatment like laser surgeri procedur
demonstr econom superior clinic equival brand
drop assum asp idos around model purpos
line istent today believ idos like price premium
price pharmacoeconom studi crystal closer launch either way
idos may struggl compet cheaper gener pharmaceut option
cheap month patient drop control
glaucoma howev newer brand drug come bausch
prostaglandin rhopressa rho kinas inhibitor
come significantli higher price tag month potenti
gain market share econom debat could quickli shift favor
idos even point could rais price devic
rate neutral trade estim next
twelve-month revenu project vs comp group comp
group compris similar high growth high multipl medic technolog
compani forecast revenu growth
comp group project grow
believ product offer novel solut treatment
variou form glaucoma growth near-term constrain limit
applic combin cataract procedur physician feedback
mix valuat reflect signific premium share result
futur product believ littl room execut error
midst grow competit within combination-cataract market
futur applic pharmaceut limit upsid share
btig publish price target neutral-r stock
risk rate includ competit exist new player
devic pharmaceut clinic efficaci pipelin product physician
reimburs risk price eros on-go patent litig
quarterli earn call quarterli earn biggest singl indic
success quarter provid detail
commerci progress go believ import metric
revenu growth beyond revenu growth believ speak
new physician on-go physician adopt istent famili
product competit dynam price addit discuss around
payer coverag reimburs rate materi impact
new product develop full pipelin new product
expand commerci opportun fulli address
glaucoma market investor close monitor progress
product way toward respect commerci launch
highlight time new product introduct page
clinic research multipl studi current on-go chief
among clinic studi ph trial idos addit trial
progress istent infinit istent sa istent supra data
alreadi publish istent istent inject research could come
compar product either exist treatment futur competit
mig devic highlight clinic mileston timelin page
ntm pt entxentneutr medicaltcmdneutr medicalwmginot factset data btig research estim ex-amortev/salescagrev/ebitdacompanytickerr ptpricemarket cap
glaucoma ocular hypertens market larg global market
afflict popul number ten million global
segment market opportun combin glaucoma
cataract market compani current abl address
broader glaucoma ocular hypertens market compani aim
address analysi estim combin glaucoma/cataract
market grow stand-alon
implant mig market opportun grow
figur combin cataract total market opportun top stand-alon market opportun
begin estim combin cataract glaucoma market
estim potenti procedur grow
asp lead us market size grow
appli price pressur expect competit
enter market pressur offer earlier gener istent
lower valu orient price total market size indic base
estim annual us cataract procedur ophthalmolog
time grow annual coincid poag glaucoma
estim
us glaucoma market popul primari open angl glaucoma market primari open angl glaucoma cataract surgeri growth cataract procedur potenti mig devic address market opportun combin cataract mig popul phakic/pseudophak total oag oag popul phakic/pseuophak eye total dx treat mig devic address market opportun stand-alon mig market
forecast total avail market opportun combin
glaucoma ocular hypertens patient popul would
applic candid forthcom idos product addit
idos like recur treatment option patient time creat
increas patient popul come back treatment repeatedli
note opportun estim idos inclus
market opportun previous describ patient whether
phakic/pseudophak combin cataract would includ
calcul note one limit analysi believ
difficult handicap proport patient may use mig devic
istent istent inject combin idos would provid
addit market opportun combin therapi grow
figur total avail market opportun ocular hypertens glaucoma potenti treat
market model broader ocular hypertens glaucoma market
base us popul risk diseas begin
elev us censu tracker estim us popul meet
age use compani estim forecast us
glaucoma popul appli american ophthalmolog academi
estim incid poag use aforement
eye/pati glaucoma incid rate yield us patient eye popul
combin ocular hypertens eye popul
deriv incid rate cite ocular hypertens
studi eye/pati incid rate appli yield total patient
eye popul util asp deriv total
us popul total us popul year glaucoma market popul primari open angl glaucoma market primari open angl glaucoma poag ocular hypertens market popul oh total total total dx treat potenti idos per md visit per opportun market
address market broad ocular hypertens glaucoma market
anatom area focu
eye held orbit six muscl two obliqu four recti
attach top eye superior rectu move eye
upward travel trochlea near nose superior
obliqu move eye inward toward nose downward
attach bottom eye inferior rectu move eye
downward travel nose across front orbit
inferior obliqu rotat eye outward upward attach
insid eye medial rectu move eye inward
attach outsid eye later rectu move eye
figur musculatur eye
american academi ophthalmolog
cover insid eyelid surfac eye conjunctiva
made mucou membran beneath sclera white
outer wall eye cover surfac eyebal next
layer uvea contain choroid suppli blood
sclera retina thin complex layer aid
vision encas within retina vitreou caviti make
space insid eye fill vitreou humor jelly-lik substanc
allow light pass retina
eye provid vision light come front eye
project onto back retina interpret light send
signal optic nerv brain front section eye
cornea iri pupil len work manipul light enter eye
focu retina cornea outermost layer section
made special structur collagen work bend light focu
retina light travel anterior chamber
fluid fill chamber separ cornea iri pupil upon
reach iri light travel pupil len retina
depend light level iri work constrict high light dilat
low light pupil open iri protect retina adjust
amount light abl hit move pupil light
hit len attach wall eye zonul fiber
purpos len bend light enter eye allow vision
focus object differ distanc
move front section eye manipul light
narrow focus way hit retina function similarli
film camera light project onto retina
interpret transmit optic nerv brain
center retina depress call fovea center
field vision fovea surround macula region eye
allow fine-tun detail extend beyond macula
peripher retina area eye enabl peripher vision
american academi ophthalmolog
focu area treatment
front section eye area contain cornea pupil len
fill liquid call aqueou humor new fluid constantli replac old
fluid eye bring nutrient anatomi keep eye
inflat old fluid exit eye travel trabecular meshwork
along eye drainag angl edg cornea iri pass
schlemm canal process fluid creation transit
eye key maintain healthi level intraocular pressur iop
american academi ophthalmolog cellappl com
glaucoma develop drainag angl function improperli
caus build-up fluid front eye time lead
increas iop damag optic nerv ultim caus
blind left untreat
two type glaucoma open-angl closed-angl open-angl
common type glaucoma develop extend period
condit initi painless accompani chang
vision allow extend build iop caus potenti
seriou complic closed-angl glaucoma acut form
glaucoma iri close align drainag angl eye
iri move block drainag angl rapid build-up fluid occur
caus emerg need rapid respons caus blind
treat
sever glaucoma delin level iop normal
iop fall mmhg mm mercuri rang divid
sever glaucoma categori ocular hypertens mild moder
advanc refractori ocular hypertens begin iop rise
mmhg top mmhg patient suffer hypertens
experi minim symptom diseas progress glaucom
level consid glaucoma clinic begin iop mmhg
point condit consid mild level patient
suffer minor damag optic nerv small amount visual field loss
iop elev level mmhg glaucoma progress beyond
mild level sever condit measur symptom treatment
effort oppos iop level moder level patient
moder visual field loss damag nerv attempt treat
condit medic laser surgeri mig devic
advanc signific visual loss nerv damag occur take
medic attempt tradit surgeri shunt refractori
level nerv damag visual field loss sever patient take
medic addit attempt surgeri shunt treatment
date specif caus identifi behind incid
glaucoma though specul genet play role
said sever factor identifi increas risk develop
pressur poor blood circul identifi gener health
factor increas likelihood glaucoma far-sighted
hyperopia near-sighted myopia previou eye injuri thin cornea
optic nerv exist high iop identifi ophthalm factor
behind higher likelihood glaucoma develop
current cur treatment option glaucoma
wide rang effect option lower iop prevent progress
condit worsen damag come along drop
typic first line treatment glaucoma follow oral medic
surgic option either treatment laser tradit
oper procedur exclus bypass shunt newer less invas laser
surgeri method develop grow popular first line
treatment altern drop today drop make major initi
treatment today repres glaucoma treatment market
recent corpor present compani cite market
scope say topic eye drop make current glaucoma
treatment market drop treatment glaucoma larg
repres one five categori alpha agonist beta-block carbon
anhydras inhibitor miotic prostaglandin analog commonli
prescrib drop prescript first line treatment often
involv one prescript two may eventu need
adequ control iop alpha agonist work reduc iop reduc fluid
product increas fluid drainag beta-block lower iop reduc
fluid product carbon anhydras inhibitor work lower iop
reduc amount fluid produc eye miotic caus pupil
constrict thu increas fluid drainag reduc iop prostaglandin analog
increas fluid drainag eye lower iop
topic drop prove ineffect ophthalmologist may addit
prescrib oral medic glaucoma suffer drug come
form oral formul cai function way topic
formul oral cai proven effect reduc iop combin
topic formul even mix topic cai drug
often dose multipl time daili due sever side effect
drug regularli prescrib gener reserv sever case
case surgeri option
drop prove ineffect treat glaucoma side effect
prove intoler patient turn surgic method laser surgeri
still rel new method treatment grow popular due
minim invas natur painless abil allow patient
rapidli return normal function laser surgeri cur
provid long-term relief glaucoma allow patient reduc use
medic delay need invas tradit surgeri given
benefit center even begin recommend laser surgeri
first line treatment oppos drop
actual techniqu laser surgeri involv ophthalmologist direct
focus beam light drainag system trabecular meshwork
patient affect eye short period time sever method
perform common call trabeculoplasti
done either argon laser trabeculoplasti alt select laser
trabeculoplasti slt alt involv train power laser
focus area trabecular network allow greater fluid drainag
eye typic half trabecular network treat first
procedur need second procedur treat remaind
area perform life eye two three alt
perform use less focus less power beam slt target full
trabecular network due lower beam intens slt perform
multipl time eye addit procedur less technic
difficult alt may aid broader adopt
asid trabeculoplasti ophthalmologist perform cycloabl
glaucom eye cycloabl laser turn toward ciliari bodi
produc aqueou humor destroy certain portion tissu
thu reduc fluid product eye procedur reserv sever
case tradit less invas surgeri either fail
inappropri due invas destruct natur
medic laser surgeri method prove ineffect lower iop
ophthalmologist resort convent surgeri trabeculectomi
procedur surgeon creat passag sclera underneath
eyelid excess fluid pass effect lower iop
accord studi lander et al measur trabeculectomi
procedur follow research found trabeculectomi
achiev complet success procedur qualifi success
procedur complet success defin iop mmhg
without take addit medic follow qualifi success
defin similarli lower iop addit medic requir
surgeon may also choos option implant stent extend
suprachoroid space anterior chamber eye allow fluid
drain space absorb tissu eye
ophthalmologist attempt control iop interact
suprachoroid space centuri experienc mix
result recent gener stent clinic data alcon
cypass stent led fda approv demonstr high level
efficaci stent suprachoroid space studi hh et al
implant cypass stent conjunct cataract surgeri led
mean post-operative iop reduct mmhg howev
signific reduct iop came elev side effect
incid hypotoni within one month implant corneal edema
incid rate compar trabecular bypass
concern suprachoroid stent risk peripher anterior
sequela pa format stent failur occur pa condit form
iri adher trabecular meshwork induc spike iop
risk present trabecular bypass procedur iop return
baselin stent failur occur elev safeti concern led
view suprachoroid implant nich product patient
need greater intervent addit year alcon show
compass-xt trial higher endotheli cell loss
cataract surgeri plu cypass control find led immedi
voluntari suspens cypass market show summari
tabl compar variou product associ level
figur comparison rate across variou product procedur
establish need new treatment option
drawback pharmaceut drop
topic pharmaceut possess advantag rel cheap
often month non-invas effect taken properli
despit eyedrop come sever drawback primarili non-
complianc declin efficaci side effect
biggest driver need new novel technolog option topic
treatment accompani patient non-compli prescrib
treatment regim studi demonstr patient drop
regim non-compli time robin et al indian journal
ophthalmolog studi regard caus non-compli
rang factor discov non-compli occur due
social/environment factor lack support major life event travel
due regimen factor complex cost medic chang due
factor individu patient knowledg memori motiv due
provid factor dissatisfact commun kulkarni et al patient
prefer adher
mani patient initi control iop util one medic
efficaci declin time ocular hypertens treatment studi oht
collabor initi glaucoma treatment studi cigt found
patient need multipl medic control iop long term
case respect complianc burden addit
medic increas patient becom increasingli dissatisfi
treatment regim demonstr studi sood et al found
patient drug regim would prefer laser surgic treatment due
financi regim burden
topic glaucoma medic possess high safeti profil
side effect caus patient dissatisfact prevent use
common side effect includ cosmet chang
pigment chang iri eyelash lengthen discolor
though gener threaten non-compli
seriou side effect includ conjunctiv hyperemia ocular discomfort
burn dri mouth hypotens addit patient allerg
certain formul limit abil add medic
increas iop reduct time
drawback laser surgeri
biggest benefit laser surgeri come form abil lower
iop without need daili drop regimen lead increas
use first line treatment mild glaucoma compar trabeculectomi
trabeculoplasti offer patient painless surgeri allow much
quicker return normal function drawback procedur declin
long-term efficaci limit number procedur alt sever
laser trabeculoplasti effect lower iop either
select argon method though success rate defin iop
reach defin mmhg level seen
topic drop util slt first line option iop reduc
mmhg sharp et al intern journal ophthalmolog
notabl less topic treatment second line treatment
concurr drop regimen slt abl reduc iop baselin
mmhg peak mmhg month postop
declin mmhg month postop second slt
procedur conduct baselin iop mmhg peak iop
reduct mmhg seen month postop declin
mmhg month postop similar declin efficaci seen
success rate defin percent eye see iop mmhg
eye achiev success month first procedur
postop declin month postop
second procedur peak success rate seen month
postop though like outlier due declin
observ declin month postop khouri et al
journal ophthalm vision research similar phenomenon
seen second line alt procedur initi iop fell mmhg year
postop procedur achiev success rate defin iop
mmhg year postop success rate fallen
though iop reduct still mmhg like due select bia
mean-max follow-up iop reduct mmhg factor
inabl regularli perform alt procedur bring frame
unsustain natur reli alt long-term iop reduct
slt alt procedur possess strong safe profil low complic
rate said complic occur signific sever
common complic slt includ post-operative inflamm iop
elev treatabl iop elev requir trabeculectomi
correct seriou complic occur includ hyphema
pool blood insid anterior chamber choroid effus macular
scar among rarer complic alt common
complic post-operative iop elev iriti hemorrhag
drawback trabeculectomi
major drawback trabeculectomi includ elev rate
complic failur rate collabor initi glaucoma treatment
studi found transient periop complic rate
common complic anterior chamber bleed shallow flat
anterior chamber encapsul bleb ptosi serou choroid detach
studi suzuki et al tc chen et al estim
procedur failur rate within year
year trabeculectomi fail revis procedur perform
perform correctli effect reduc iop
declin time howev studi broadway et al see revis
success rate defin unmed iop mmhg
declin year postop year postop
glaucoma predominantli occur older popul
epidemiolog studi cover glaucoma incid rate popul
age us censu tracker estim year age popul
broader us popul equal estim
year age popul us american academi
ophthalmolog publish system review meta-analysi exist
studi estim global incid rate glaucoma among
popul break incid rate
open-angl closed-angl util
popul estim yield estim us glaucoma-afflict
popul given eye/pati inflict estim yield
estim popul afflict eye us
look rest world base american academi
ophthalmolog system review unit nation global popul age
data estim global glaucoma-afflict popul
yield global glaucoma-afflict eye popul base
unit nation estim global age age popul
multipli american academi ophthalmolog deriv global
glaucoma incid rate subtract us popul deriv
non-u base glaucoma popul yield non-u
glaucoma eye popul
ophthalm medic technolog pharmaceut compani
focus develop commerci novel surgic devic
sustain pharmaceut therapi design transform treatment
glaucoma innov micro-invas glaucoma surgeri
mig revolution tradit glaucoma treatment manag
journal clinic
istent istent trabecular micro-bypass stent pma approv first-
gener stent use conjunct cataract surgeri reduct
intraocular pressur adult patient mild moder open-angl
glaucoma current treat ocular hypertens medic istent
deliv insert consist dispos instrument
istent tip insert implant clear corneal
incis similar iol would insert tip stent
place schlemm canal via trabecular meshwork button
press devic releas
istent inject istent inject second gener microst inject
system indic use conjunct cataract surgeri
reduct intraocular pressur iop adult patient mild moder
primari open angl glaucoma istent inject creat two open along
trabecular meshwork allow aqueou fluid outflow eye similar
istent injector system upon press button releas istent
inject proper locat stent place degre
apart around eye note stent use istent inject roughli
one-third size previou gener istent
istent infinit istent infinit design stand-alone procedur
titanium stent preload auto-inject system current
estim infinit approv use fda late
istent sa decemb began trial istent sa
stand-alon istent sa micro-bypass system similar legaci
istent istent inject indic stand-alon procedur iop
reduct oppos use combin cataract target
approv sa current sit
istent supra istent supra intend reduc intraocular pressur
access suprachoroid space eye supra devic similar
competit product market today focu
suprachoroid space account aqueou outflow stent
heparin-co combin polyethersulfon medic grade
titanium supra stent larger tradit stent length
lumen size product ce mark
current clinic trial us expect fda approv
idos idos implant use microst platform idos
design preload insert system inject eye
titanium implant design continu drug deliveri
directli anterior chamber eye first formul use
travoprost prostaglandin analog use reduc intra-ocular pressur
travoprost elut control membran continu deliv
medic within eye extend period time drug
deplet idos stent remov replac similar procedur
fda approv idos expect come either late
rho kinas inhibitor august sign
agreement rate partner
develop intraocular product treat glaucoma use western
proprietari inhibitor compound current portfolio
two inhibitor glanatec commerci approv
japan south korea also refer
undergo ph clinic trial japan addit also multi-
kinas inhibitor current ph studi kaneko et al glanatec
found reduc iop line topic drop exhibit
similar safeti profil addit inhibitor function differ way
topic treatment mean inhibitor could potenti
work complimentari fashion treatment
encapsul commerci clinic histori figur
well project commerci clinic mileston year ahead
figur commerci clinic histori
figur estim clinic commerci mileston
date tent base compani estim clinicaltri gov
istent fda approvalinternationallaunchcontrol inject launch germanygko ipo closesaustraliaapprovesinjectinject complet us pivot enrollmentcanada approvesinjectidos ind filedcanadianinjectlaunchaustralianinjectlaunchist japanes approvalfda inject fulli enrolledfda supra pivot fulli enrolledacquir iop sensor dose medicalph ii idos enrol completedfda injectpivot resultsfda approvesinjectd western ph completionsa ph iv completioninject dataread outsa ph iv completionsa data read outinject studycompletionsupra ph iv read outsupra ph iv completionsa studi completionsupra approvalsupra ph iv completionidos ph ii completioninfiniteapprovalist ph iv read outinject dataread outidos ph read outist ph iv completioninjectstudycompletioninfinit studycompletionidos ph completionidos approvalidos ph completionsa fda approvalinternationallaunchcontrol inject launch germanygko ipo closesaustraliaapprovesinjectinject complet us pivot enrollmentcanada approvesinjectidos ind filedcanadianinjectlaunchaustralianinjectlaunchist japanes approvalfda inject fulli enrolledfda supra pivot fulli enrolledacquir iop sensor dose medicalph ii idos enrol completedfda injectpivot resultsfda approvesinjectd western ph completionsa ph iv completioninject dataread outsa ph iv completionsa data read outinject studycompletionsupra ph iv read outsupra ph iv completionsa studi completionsupra approvalsupra ph iv completionidos ph ii completioninfiniteapprovalist ph iv read outinject dataread outidos ph read outist ph iv completioninjectstudycompletioninfinit studycompletionidos ph completionidos approvalidos ph completionsa
peer review public involv product
portfolio review key clinic studi across varieti product
includ earli clinic work istent recent public
product istent inject supra idos
random evalu trabecular micro-bypass stent
phacoemulsif patient glaucoma cataract samuelson et al
american academi ophthalmolog
pivot trial led approv devic focu studi
evalu safeti efficaci istent two-year period
treat eye twelv month treat eye lower iop
mmhg without medic greater reduct
iop without medic
trabecular micro-bypass stent implant small-incis cataract
surgeri open-angl glaucoma ocular hypertens long-term result
neuhann et al journal cataract refract surgeri
focu studi evalu long-term safeti efficaci
istent cataract surgeri studi occur europ eye
amongst patient mean iop hg patient take
mean medic follow istent insert iop reduc
mm hg month mm hg month
mm hg month medic elimin eye
combin istent trabecular micro-bypass stent implant
phacoemulsif coexist open-angl glaucoma cataract long-
term studi villalobo et al british journal ophthalmolog
intervent case seri patient enrol mean follow-up
month mean iop reduc mm hg mm
hg end follow indic decreas iop mean
number pressure-low medic use patient fell
patient antiglaucoma medic use
end follow-up
figur villalobo et al real world experi uk
clinic evalu trabecular microbypass stent phacoemulsif
patient open-angl glaucoma cataract ferguson et al journal
retrospect case seri octob decemb compris
eye oag cataract treat istent mean preoper
iop mm hg year post-op mean iop fell mm
hg mean number glaucoma medic preoper
fell year post-op
figur ferguson et al real world experi us
istent inject us pivot trial prospect random multi-cent
clinic trial site open-angl glaucoma subject
random istent inject combin cataract surgeri
subject random cataract subject follow
month month istent inject cohort achiev greater
reduct iop compar control arm mean iop
reduct mm hg istent inject vs hg control
consecut case seri studi primarili oag eye implant istent
inject combin cataract surgeri henger ophthalmolog
prospect non-random consecut case seri conduct
univers heidelberg compris eye glaucoma subject
cohort mean preoper iop mmhg mean preoper
number topic medic three year mean post-operative iop
fallen mmhg fall mmhg fall
mmhg mean medic burden fell time period
mean post-operative number eye requir reduc
medic abl go medic free
figur henger et al istent inject
retrospect single-sit case seri eye vari glaucoma sever
concomit cataract surgeri harasymowycz ascr
retrospect case seri observ eye patient measur
reduct iop medic usag mean preoper iop
mmhg mean preoper medic usag month
year data readout mean post-operative iop reduc
mmhg mean medic use reduc
medic patient reduc medic use one
patient reduc medic use two
figur harasymowycz et al istent inject
outcom follow implant two second-gener trabecular micro-
bypass stent patient open-angl glaucoma one medic
lindstrom et al advanc therapi
prospect studi observ eye preoper one medic
iop mmhg wash iop mmhg twelv month
unmed iop decreas mean mmhg
eye achiev iop reduct iop mmhg iop
declin mean post-operative level mmhg
month month month readout respect
figur lindstrom et al istent sa
prospect random studi one two three trabecular bypass stent
open-angl glaucoma subject topic hypotens medic katz et al
journal clinic ophthalmolog decemb
prospect random studi compar efficaci implant
variou number stent topic medic wash subject
implant one stent two three month
subject one stent subject two
subject three experienc iop reduct vs wash level
iop mmhg respect group
achiev unmed iop mmhg month follow one
stent two stent three stent group mean iop
figur katz et al istent infinit
januari announc interim data ph ii trial compar
efficaci fast elut slow elut idos implant topic timolol
beta blocker control group interim data demonstr
mmhg iop reduct fast elut slow elut idos group
respect minim advers event compar posit
topic timolol control group saw iop reduct
mmhg studi expect complet decemb
figur earli clinic data idos elut rate
istent current one on-go trial activ recruit
aim evalu long-term safeti devic trial
compar sight-threaten advers event subject
undergon cataract surgeri istent implant subject
exclus undergon cataract surgeri studi also aim
compar iop reduct procedur studi expect
complet juli
sever on-go clinic studi look istent inject trial
nearest expect complet decemb evalu
efficaci devic reduc iop compar iop reduct subject
cataract surgeri istent inject implant versu
exclus cataract surgeri second expect complet
septemb compar efficaci devic compar
istent sa three clinic studi on-go accord
clinicaltri gov evalu efficaci devic compar
topic medic first versu one topic medic complet
may second versu two topic medic complet
april third studi evalu efficaci safeti devic
combin cataract surgeri expect complet june
trialstartedread outproject endprimari endpointsecondari endpoint- adverseevents- diurnal iopreduct sight-threaten adverseeventstrialstartedread outproject endprimari endpointsecondari endpoint- number glaucoma medic years- treatment reduct month onsam fewermedicationsn/aiop outproject endprimari endpointsecondari endpointph reduct iop vs medic baselin monthsiop mmhgv medic baselin monthsph reduct iniop monthsiop months- qualiti lifeimprovement- advers reduct iop month
istent supra current process collect two-year follow data
trial measur safeti efficaci devic
conjunct cataract surgeri primari endpoint trial
measur percentag patient experi reduct iop
secondari endpoint diurnal iop reduct trial control
patient undergo exclus cataract surgeri full two-year follow data
expect collect januari full trial complet
april accord clinicaltri gov
devic also evalu two trial evalu
efficaci supra lower iop conjunct separ istent
devic one trial evalu supra conjunct one istent post
cataract surgeri evalu supra conjunct two
istent infinit one trial on-go accord clinicaltri gov
evalu efficaci safeti devic primari endpoint
trial measur chang diurnal iop studi commenc
juli plan enrol patient target complet
septemb
current conduct two pivot ph trial addit on-
go ph ii trial trial current recruit patient measur
efficaci idos devic compar placebo group initi data read-
out trial expect come trial involv
idos devic measur efficaci high low elut cohort
direct sale oper within unit state
intern direct sale countri plu addit distribut
partner distributor organ numer countri
decemb estim sale profession within
us intern offici rep product target
establish management comment sale rep abl
grow product significantli higher level tradit level seen
compar medic technolog compani peak product
potenti reach level north due eas speed
istent product insert convert
doctor potenti becom high-volum user quickli case
coverag may necessari follow physician convers
outsid direct sale distributor network commerci
infrastructur contain larg outfit personnel insid outsid
us focus payor reimburs support personnel aid
effort eas administr burden item insur
verif claim process revenu cycl manag task
view signific advantag competit believ
group help significantli improv dynam gain
coverag outsid us believ sale infrastructur limit
friction process ultim speed reimburs
figur direct green indirect blue sale infrastructur
facil reimburs istent paid via categori code current
istent categor describ insert
istent well istent inject istent sa istent infinit code
began effect year appli addit
extens allow code last current glauko
reimburs heavili tie medicar payment rate cataract
surgeri paid via center medicar medicaid servic
typic privat payer
current label istent insert perform outpati set
either outpati hospit sinc procedur
perform conjunct cataract procedur medicar pay rate
first procedur whichev higher amount plu second
rate lower amount two given cataract reimburs lower
istent insert cataract reimburs facil paid lower
rate valu use conjunct istent
also import note medicar pay separ
reimburs sole istent payment istent includ
facil reimburs apc
physician reimburs istent insert current nation
medicar establish payment rate payment determin made
medicar administr contractor split unit state
variou region current cover istent insert variat
exist amongst istent insert profession fee amount pleas
see chart provid facil rate well
figur glauko reimburs code associ amount
ambulatori surgic hospit outpati physician feeassoci glauko anterior segment aqueou drainag devic without extraocular reservoir intern approach trabecular meshwork initi macist istent addit devic insertionbundledbundledvari macist istent anterior segment aqueou drainag devic without extraocular reservoir intern approach suprachoroid macist cataract extract remov insert intraocular len prosthesi one stage procedur manual mechan techniqu cataract extract insert intraocular len prothesi stage cataract remov insert intraocular len prosthesi stage procedur manual mechan techniqu eg irrig aspir
figur physician payment rate istent insert geographi
robust patent portfolio compris issu
licens pend patent applic decemb glauko
patent portfolio includ numer patent gen-on istent trabecular
len well futur product forthcom review patent
note earliest expir would relat key patent istent
istent inject mani patent carri well beyond base
review publish patent
york york long york rest york york suburban york rest east st rest new rest fort rest metro rest rest rest kansa st rest codecpt code
april file patent infring lawsuit ivanti
alleg ivanti hydru microst devic infring
patent specif note patent
specif infring upon ivanti respond may
request invalid istent patent uspto
offic patent question grant
ivanti alleg certain claim made patent obviou
base previou public surgic textbook entitl surgic
glaucoma therapi invalid document also reli prior
australian patent us patent addit note ivanti file
counterclaim august alleg
infring ivanti patent specif us patent
convers management
regulatori file note court hear motion march
regard patent disput trial set februari
thoma burn presid ceo mr burn serv member
board director sinc march also current
serv member board director dose medic corpor
role held sinc octob previous presid ceo
dose medic eyetech pharmaceut inc serv leadership
role chiron vision corpor bausch lomb mr burn receiv
 yale univers
chri calcaterra mr calcaterra serv current role sinc
februari previous serv chief commerci offic sinc april
prior join serv leadership role advanc medic
optioc allergan inc mr calcaterra receiv miami univers
 xavier univers
joseph gilliam cfo svp corpor develop mr gilliam
serv current posit sinc may spent nearli
year role across bank capit market strateg advisori
jpmorgan beacon group pricewaterhousecoop mr gilliam
receiv kelley school indiana univers
jane radi svp corpor strategi busi develop ms
radi join initi serv vice-president busi develop
ascend current role april prior join
ms radi serv busi develop role johnson johnson surgic
vision abbott medic optic receiv biolog
molecular biology/microbiolog univers illinoi
kellogg school northwestern univers
 jay katz md fac chief medic offic dr katz serv
current role sinc februari practic ophthalmologist
sinc current serv professor ophthalmolog jefferson
medic colleg director glaucoma servic will hospit
dr katz receiv case western reserv univers
yale univers medic school complet internship univers
virginia resid yale univers
market leader minim invas glaucoma stent
technolog multipl compani offer stent primarili
suprachoroid physician may opt use either replac istent
conjunct istent
figur stent portfolio rel competit
alcon global leader eye care divis novarti alcon offer
broadest portfolio product enhanc sight improv peopl live
alcon product touch live million peopl year
live condit like cataract glaucoma retin diseas refract
error million wait solut meet
relat specif mig market alcon offer cypass micro-
stent cypass ultra system cypass micro-st polyimid
tube fenestr lumen length stent design
placement angl eye place stent allow
outflow aqueou fluid cypass ultra system use conjunct
micro-st placement stent eye indic
cypass mild moder primari open angl glaucoma poag
august alcon withdrew cypass market follow long-
term safeti data compass-xt studi show statist
signific endotheli cell loss certain patient year current alcon
work fda determin appropri label chang
possibl cypass could come back market although convers
industri sceptic
allergan plc headquart dublin ireland global pharmaceut
compani focus develop manufactur commerci brand
pharmaceut devic biolog surgic regen medicin product
patient around world allergan market portfolio lead brand
best-in-class product central nervou system eye care medic
aesthet dermatolog gastroenterolog women health urolog
relat minim invas glaucoma allergan offer xen glaucoma
treatment system compris xen gel stent xen
injector xen gel stent design reduc intraocular pressur
eye suffer refractori glaucoma devic creat perman
channel sclera allow flow aqueou humor
anterior chamber subconjunctiv space stent compos
gelatin deriv porcin dermi form tube
cross link glutaraldehyd stent length
allergan current develop two sustain releas treatment
glaucoma bimatoprost sr bimatoprost ocular ring sr
biodegrad inject implant provid sustain releas
bimatoprost four-month period two ph pivot trial recent
announc top line data implant demonstr non-inferior
timolol topic drop control iop reduct lower iop
accept safeti profil previou studi demonstr iop reduct
week mmhg depend dosag lower advers
event topic bimatoprost allergan plan file nda
implant bimatoprost ocular ring insert
eyelid six-month interv demonstr iop reduct mmhg
six month safeti in-lin topic control ph i/ii trial
complet may develop mileston ring
yet establish
ivanti inc privat held compani establish design develop
commerci new technolog treat eye diseas investor includ
innov fund merieux develop vertex healthcar compani
headquart irvin california
hydru microst implant flexibl metal nitinol tube
hydru microst intend reduc eye pressur intraocular pressur
iop adult patient mild moder primari open angl glaucoma
poag act support structur one part natur drainag
pathway eye schlemm canal clinic studi particip
receiv hydru microst achiev greater
reduct iop compar particip
publicli trade biopharmaceut compani focus
treat condit eye compani found
headquart bedford compani current two treatment
clinic trial intend use treatment glaucoma otx-tp otx-
otx-tp intracanalicular depot design deliv travoprost
eye period depot drug formul contain within
hydrogel case resorb drug fulli elut treatment
current evalu ph pivot trial expect data
readout otx-tic bioresorb travoprost implant insert
inject design deliv drug four-to-six-month
period treatment current evalu ph trial test safeti
durabl efficaci toler
publicli trade compani establish
headquart osaka japan compani focus
develop pharmaceut includ prescript ophthalm anti-
rheumat drug well over-the-count drug compani also
produc medic devic equip sale larg gener japan
smaller oper asia emea
term glaucoma treatment santen produc sever prescript eye
drop medic treatment elev iop includ prostaglandin
beta blocker among largest gross treatment current
compani progress sever new pharmaceut treatment glaucoma
us japan asia also develop microshunt treatment
us europ
ellex medic laser publicli trade compani found
develop produc laser ultrasound system use diagnos
treat ophthalm condit use treatment glaucoma
compani develop tango tango reflex surgic laser use slt
procedur well itrack surgic system use canaloplasti
procedur compani offer medic implant
iridex corpor publicli trade compani found
develop produc medic devic ophthalmolog market
treat glaucoma iridex offer micropuls laser system micropuls
laser trabeculectomi len g-probe g-probe product use
compani micropuls laser trabeculectomi procedur
procedur continuous-wav laser broken low energi puls unlik
standard slt laser wave appli continu fashion
johnson johnson world largest healthcar compani oper
three segment consum medic devic johnson
johnson vision lie within medic devic segment offer treatment
visual acuiti cataract laser surgeri glaucoma among condit
eye
lumeni privat held compani design develop manufactur
solut aesthet surgic ophthalmolog market
treatment glaucoma compani produc selecta ii smart selecta
duet trio aura pt laser us slt procedur
mati privat held compani develop punctal
drug deliveri system treatment condit eye
treatment glaucoma compani current progress clinic trial
util latanoprost formul mati also addit
glaucoma agent progress preclin work wait
advanc clinic
neomedix privat held compani design develop
manufactur micro-surg solut treatment adult infantil
glaucoma compani develop trabecutom util
electrosurg puls excis trabecular meshwork goniotom
uniqu design tool use tradit blade excis
new world medic privat held compani design develop
manufactur product treatment glaucoma first product
compani produc kahook dual blade uniqu design surgic
blade use excis trabecular meshwork second ahm
glaucoma valv valv insert pocket creat beneath
episclera drain tube anterior chamber
pocket seal allograft conjunctiva tissu
sight scienc commercial-stag medic devic compani dedic
develop intellig design engin product
address underli physiolog ophthalm diseas sight scienc
surgic glaucoma product portfolio featur omni surgic system
predecessor devic non-surg dri eye product
portfolio consist tearcar ophthalmologist optometrist
staar surgic publicli trade compani found develop
manufactur product treatment ocular condit
primari focu intraocular implant lens refract condit
cataract treat glaucoma staar offer aquaflow collagen
glaucoma drainag devic minim invas implant
insert schlemm canal aid fluid drainag iop reduct
viscocanalostomi techniqu use insert devic gener view
safer trabeculectomi less effect lower iop
incom etot y/i sale oper incom incom tax expens net incom share oper expens btig research estim compani report
revenu eproduct growth growth btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
